Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers

Therapeutic Advances in Respiratory Disease
Franco PasquaMario Cazzola

Abstract

Smoking is associated with an increased risk of respiratory tract infection in adults likely because components in the smoke might alter properties of the epithelial cell surface. In studies with smokers suffering from acute exacerbations of COPD (AECOPD), the most common bacterial pathogens found were mainly Haemophilus influenzae, but also Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis. Therefore, antibiotics should be effective against such possible pathogens. Prulifloxacin has demonstrated in vitro activity against all these pathogens. We designed the present study to evaluate the efficacy of prulifloxacin in the treatment of AECOPD in cigarette smokers. We enrolled 61 consecutive smokers hospitalized or out-patients of either sex with symptoms and signs compatible with the usual diagnosis criteria for AECOPD. Haemophilus influenzae was the most common bacterial species isolated in the sputum (in 42.6% of the total sample), followed by S. pneumoniae (16.5%), S. aureus (14.7%), M. catarrhalis (11.5%), and others (14.7%). Prulifloxacin 600 mg was given orally once daily for 10 days. Clinical success was observed in 91.8% of patients (67.2% cured and 24.6% improved). Bacteriological eradication rate...Continue Reading

References

Jul 1, 1979·Journal of Clinical Pathology·D Roberts, P Cole
Dec 1, 1992·American Journal of Public Health·S SheaC K Francis
Jan 1, 1987·Infection·R B Brown
Aug 1, 1997·The American Journal of Medicine·S E McNagnyK A Resnicow
Feb 25, 1999·FEMS Immunology and Medical Microbiology·O R El AhmerC C Blackwell
Mar 5, 1999·The European Respiratory Journal·E MonsóJ Morera
Mar 5, 1999·The European Respiratory Journal·R ZalacainJ L Llorente
May 4, 1999·The Journal of Antimicrobial Chemotherapy·S Sethi
Apr 5, 2000·Seminars in Respiratory Infections·R F Grossman
Jul 14, 2000·Chest·T F MurphyM S Niederman
Jun 20, 2002·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G PratsB Mirelis
Jul 2, 2003·Expert Opinion on Investigational Drugs·Francesco BlasiLuigi Allegra
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
May 1, 2004·American Journal of Respiratory and Critical Care Medicine·Timothy F MurphySanjay Sethi
Dec 17, 2005·Pulmonary Pharmacology & Therapeutics·Mario Cazzola, Claudio Ferdinando Donner
Dec 20, 2005·Pulmonary Pharmacology & Therapeutics·Mario CazzolaLuigi Allegra
Dec 20, 2005·Pulmonary Pharmacology & Therapeutics·Maria Gabriella Matera
Feb 14, 2006·American Journal of Respiratory and Critical Care Medicine·Sanjay SethiCharles S Berenson
Apr 1, 2006·American Journal of Respiratory and Critical Care Medicine·Charles S BerensonSanjay Sethi
Mar 14, 2007·Diagnostic Microbiology and Infectious Disease·Antonio AnzuetoSudha Pottumarthy
Sep 18, 2007·American Journal of Respiratory Cell and Molecular Biology·Gordon J GaschlerMartin R Stämpfli

❮ Previous
Next ❯

Citations

Feb 9, 2011·International Journal of Antimicrobial Agents·Petros I RafailidisMatthew E Falagas
Apr 1, 2019·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jürgen KnoblochAndrea Koch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

Pulmonary Pharmacology & Therapeutics
Maria Gabriella Matera
International Journal of Chronic Obstructive Pulmonary Disease
Francesco BlasiLuigi Allegra
© 2021 Meta ULC. All rights reserved